Compare Novartis AG (NVS) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Valero Energy Corporation — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Valero Energy Corporation trades at $314.5 (market cap $93.03B). The key difference: Novartis AG is far larger — about 3.1× Valero Energy Corporation's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | VLO | |
|---|---|---|
Market Cap | $290.25B | $93.03B |
Sector | Health | Energy |
52-Week High | $168.62 | $313.31 |
52-Week Low | $113.50 | $131.77 |
Enterprise Value | $330.27B | $98.79B |
Dividend Yield | 3.17% | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Valero Energy (VLO) trades at $314.80, up 1.66% today and near its 52-week high, with a bullish technical outlook supported by strong moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 expected at $10.13 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 3.37%, while valuation ratios like P/E of 22.89 and P/S of 0.77 reflect moderate pricing relative to peers. Recent news highlights robust refining margins and dividend declarations of $1.20 per share.
VLO's outlook is positive due to elevated crack spreads and strong fuel demand, though revenue declines pose a risk. Analyst consensus is bullish with a $285.38 price target, but high RSI levels suggest potential near-term pullbacks. Investment appeal lies in earnings momentum and shareholder returns, balanced against exposure to volatile energy markets and refining margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
